top of page

In CTEPH, antioxidant enzyme PRDX2 reduces inflammation

A study found that chronic thromboembolic pulmonary hypertensio (CTEPH) patients had significantly more of an antioxidant enzyme (peroxiredoxin 2, or PRDX2) in their bloodstream compared to healthy patients. Using rats, the researchers determined that PRDX2 helped reduce inflammation, suggesting that it has a protective role and might have therapeutic use.


 
 
 

Recent Posts

Biomarkers identified for high-altitude PH

This study looked at which proteins and metabolic biomarkers might be associated with the development of high-altitude pulmonary hypertension (PH). Looking at data from China, from rat tissues, and fr

 
 
 
Smoking delays PAH diagnosis, but not CTEPH

Researchers looked at whether cigarette smoking affected the diagnosis and disease progression of patients with pulmonary arterial hypertension (PAH) and chronic thromboembolic pulmonary hypertension

 
 
 

Comments


PHA Canada

408 - 55 Water Street

Office 8928

Vancouver, BC, V6B 1A1

Email: info@phacanada.ca

Phone: 604-682-1036

Toll Free: 1-877-774-2226

  • Instagram
  • Facebook
  • X
  • LinkedIn
  • Youtube

Charitable Registration # 872050224RR0001

Copyright 2025 PHA CANADA, ALL RIGHTS RESERVED   |   Website created by Creativibe   |   Powered by raisin

bottom of page